AveXis (AVXS) Given a $143.00 Price Target by UBS Group Analysts
UBS Group set a $143.00 price target on AveXis (NASDAQ:AVXS) in a research report sent to investors on Wednesday, thefly.com reports. The firm currently has a buy rating on the stock. The analysts noted that the move was a valuation call.
Several other equities analysts have also recently issued reports on the company. Bank of America dropped their target price on AveXis from $115.00 to $112.00 and set a buy rating on the stock in a research report on Friday, November 10th. Chardan Capital restated a buy rating on shares of AveXis in a report on Thursday, November 2nd. BMO Capital Markets restated a buy rating and issued a $150.00 price target on shares of AveXis in a report on Thursday, January 18th. William Blair restated a buy rating on shares of AveXis in a report on Tuesday, January 30th. Finally, BidaskClub cut AveXis from a hold rating to a sell rating in a report on Thursday, December 14th. Three research analysts have rated the stock with a sell rating, three have issued a hold rating and sixteen have issued a buy rating to the company’s stock. AveXis currently has a consensus rating of Buy and a consensus target price of $123.45.
AveXis (NASDAQ:AVXS) opened at $130.19 on Wednesday. AveXis has a 52-week low of $63.61 and a 52-week high of $132.66.
In related news, VP Andrew F. Knudten sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $118.13, for a total value of $236,260.00. Following the sale, the vice president now owns 7,000 shares of the company’s stock, valued at approximately $826,910. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Brian K. Kaspar sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $118.07, for a total value of $1,771,050.00. Following the completion of the sale, the insider now directly owns 1,792,147 shares in the company, valued at approximately $211,598,796.29. The disclosure for this sale can be found here. In the last ninety days, insiders sold 40,780 shares of company stock worth $4,570,422. 18.60% of the stock is owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of the stock. Janus Henderson Group PLC lifted its stake in AveXis by 52.2% in the 3rd quarter. Janus Henderson Group PLC now owns 1,027,221 shares of the company’s stock valued at $99,363,000 after buying an additional 352,456 shares in the last quarter. Perceptive Advisors LLC lifted its stake in AveXis by 147.5% in the 3rd quarter. Perceptive Advisors LLC now owns 671,181 shares of the company’s stock valued at $64,923,000 after buying an additional 400,000 shares in the last quarter. Westfield Capital Management Co. LP purchased a new stake in AveXis in the 3rd quarter valued at approximately $39,563,000. Eagle Asset Management Inc. lifted its stake in AveXis by 123.4% in the 4th quarter. Eagle Asset Management Inc. now owns 354,154 shares of the company’s stock valued at $39,274,000 after buying an additional 195,626 shares in the last quarter. Finally, Deutsche Bank AG lifted its stake in AveXis by 42.7% in the 4th quarter. Deutsche Bank AG now owns 303,901 shares of the company’s stock valued at $33,630,000 after buying an additional 90,934 shares in the last quarter. 82.66% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/03/04/avexis-avxs-given-a-143-00-price-target-by-ubs-group-analysts.html.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.